RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE …
WEB3 days ago · Recordati (REC.MI) is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271) uniquely structured to bring treatment across specialty and primary care and ...
In sustained rare disease push, Recordati lays out $825M upfront …
WEB3 days ago · Enjaymo reeled in sales of around 100 million euros ($110 million) over 12 months ending in August, Recordati said in its release. The drug is expected to generate revenues in the vicinity of 150 ...
Recordati buys rights to rare immune disorder drug from Sanofi …
WEB3 days ago · Recordati said it had signed an agreement for the rights to Enjaymo, a biologic which is the only targeted product for the treatment of CAD approved by the U.S. Food and Drug Administration (FDA).
Sanofi Drug for Rare Blood Disease Is Heading to Recordati for …
WEB3 days ago · Recordati said that in the 12 months ending in August, the drug accounted for €100 million (about $109 million) in revenue. The company projects the product’s peak sales could reach €250 ...
Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For …
WEB2 days ago · On Friday, Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY) for $825 million as an upfront payment and additional ...
Sanofi Offloads Rare Autoimmune Drug to Recordati in
WEB3 days ago · Sanofi sold Enjaymo, its humanized monoclonal antibody treatment for the rare autoimmune disorder cold agglutinin disease, to Italy’s Recordati in an agreement potentially worth more than $1 billion.. Under the terms of the deal, Milan-based Recordati will pay $825 million upfront and will pledge up to $250 million in sales-based milestones.
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE …
WEB4 days ago · Recordati (REC.MI) is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271) uniquely structured to bring treatment across specialty and primary care and ...
Recordati to Buy Global Rights to Sanofi's Enjaymo for $825 Million
WEB3 days ago · Recordati reached an agreement with French pharmaceutical company Sanofi to acquire the global rights to autoimmune disorder treatment Enjaymo for $825 million. The Italian pharmaceutical company ...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE …
WEB3 days ago · Milan, 4 th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.. Enjaymo® (sutimlimab) is a humanized monoclonal antibody indicated for the treatment of hemolysis in adults ...
Recordati shares rise as investors reportedly circle CVC stake
WEBJun 18, 2024 · Shares in Italian drugmaker Recordati rose almost 3% on Tuesday, boosted by a report that investment funds KKR and TPG had expressed preliminary interest in buying a stake in the company.